MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.610
-0.010
-0.38%
Closed 16:00 08/12 EDT
OPEN
2.650
PREV CLOSE
2.620
HIGH
2.670
LOW
2.590
VOLUME
218.03K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
1.500
MARKET CAP
148.88M
P/E (TTM)
-7.6093
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GALT stock price target is 6.50 with a high estimate of 9.00 and a low estimate of 4.000.

EPS

GALT News

More
Galectin Therapeutics EPS misses by $0.04
Galectin Therapeutics (NASDAQ:GALT): Q2 GAAP EPS of -$0.11 misses by $0.04. Cash and cash equivalents of $40.8M.  Press Release
seekingalpha · 2d ago
Galectin Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent decrease over losses of $(0.06) per
Benzinga · 2d ago
Revance Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/03 06:07
Galectin launches new study of lead drug in NASH
Seeking Alpha - Article · 06/30 15:22
UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
GlobeNewswire · 06/30 14:05
Galectin Therapeutics Announces Commencement Of Patient Enrollment Of The Adaptively-Designed Phase 2b/3 Trial Of Belapectin In NASH Cirrhosis
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient
Benzinga · 06/30 12:05
ENDRA Life Sciences' NASH Test Device, TAEUS, At Commercialization Inflection Point
Seeking Alpha - Article · 06/20 00:40
Hedge Funds Are Souring On Galectin Therapeutics Inc. (GALT)
Insider Monkey · 06/05 02:48

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About GALT

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
More

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.